Table 2.

Clinicopathological characteristics according to BRAF V600E and SRC mutation status.

Variable	Modality	BRAF V600E and SRC status
		Both BRAF V600E and SRC wild-typea (N = 90)	BRAF V600E (N = 7)	SRC mutant (N = 14)	P-valueb	P-valuec
Age (years)	<65	52 (47)	3 (3)	7 (6)	0.667	0.999
	≥65	38 (34)	4 (4)	7 (6)
Sex	Male	54 (49)	2 (2)	10 (9)	0.164	0.159
	Female	36 (32)	5 (4)	4 (4)
Tumor size (mm)	<50	33 (30)	0 (0)	3 (3)	0.088	0.521
	≥50	57 (51)	7 (6)	11 (10)
Pre-operative CEA (ng/ml)	<200	69 (62)	7 (6)	9 (8)	0.190	0.123
	≥200	21 (19)	0 (0)	5 (4)
Primary tumor site	Right-sided	25 (23)	6 (5)	3 (3)	0.004	0.016
	Left-sided	65 (58)	1 (1)	11 (10)
Histopathological grading	G1, 2	67 (60)	1 (1)	10 (9)	0.004	0.024
	G3	23 (21)	6 (5)	4 (4)
T category	T2, 3	44 (40)	1 (1)	2 (2)	0.015	0.999
	T4	46 (41)	6 (5)	12 (11)
N category	N0	13 (12)	0 (0)	2 (2)	0.558	0.533
	N1, 2	77 (69)	7 (6)	12 (11)
M category	M1a	47 (42)	3 (3)	6 (5)	0.742	0.999
	M1b	43 (39)	4 (4)	8 (7)
Liver metastasis	Absent	18 (16)	4 (4)	1 (1)	0.027	0.025
	Present	72 (65)	3 (3)	13 (12)
Lung metastasis	Absent	63 (57)	4 (4)	10 (9)	0.764	0.638
	Present	27 (24)	3 (3)	4 (4)
Peritoneal metastasis	Absent	74 (67)	4 (4)	11 (10)	0.273	0.354
	Present	16 (14)	3 (3)	3 (3)
Liver-limited metastasis	Absent	51 (46)	6 (5)	7 (6)	0.269	0.174
	Present	39 (35)	1 (1)	7 (6)
Number pf metastatic sites	1	51 (46)	5 (4)	8 (7)	0.748	0.656
	≥2	39 (35)	2 (2)	6 (5)
Residual tumor	R0	41 (37)	1 (1)	3 (3)	0.080	0.593
	R2	49 (44)	6 (5)	11 (10)

^aSix patients with BRAF non-V600E mutation were included.

^bThe three groups (BRAF and SRC wild-type, BRAF V600E, SRC mutant) were compared using a Pearson’s chi-squared test.

^cBRAF V600E versus SRC mutant were compared using a Fisher’s exact test (two-tailed).